Steroids in neurooncology: Actions, indications, side-effects

Current Opinion in Neurology

Volumn 23, Issue 6, 2010, Pages 597-602

  Roth, Patrick ^a   Wick, Wolfgang ^b   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

brain tumor; edema; glucocorticoid

Indexed keywords

BEVACIZUMAB; CALCIUM ACTIVATED POTASSIUM CHANNEL; COTRIMOXAZOLE; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; HYDROCORTISONE; PENTAMIDINE; PHENYTOIN; VASCULOTROPIN;

ADRENAL CORTEX ATROPHY; ADULT; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN METASTASIS; BRAIN TUMOR; CATARACT; CELL DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EDEMA; GLIOBLASTOMA; GLIOMA CELL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INTRACRANIAL PRESSURE; LYMPHOCYTOPENIA; LYMPHOMA; LYMPHOMA CELL; MORNING DOSAGE; MYALGIA; MYOPATHY; NAUSEA; NONHUMAN; OSTEOPOROSIS; PERIPHERAL EDEMA; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; REVIEW; SIDE EFFECT; TREATMENT RESPONSE; TUMOR CELL;

AUTOPHAGY; BRAIN EDEMA; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GLUCOCORTICOIDS; HUMANS; INTRACRANIAL HYPERTENSION; LYMPHOMA; RISK ASSESSMENT; TIME;

EID: 78649632130     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32833e5a5d     Document Type: Review

References (88)

1. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000; 21:55-89.
2. Nicolaides NC, Galata Z, Kino T, et al. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010; 75:1-12.
3. Ruderman NB, Hall TC. Use of glucocorticoids in the palliative treatment of metastatic brain tumors. Cancer 1965; 18:298-306.
4. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362:847-849.
5. Smith KG, Strasser A, Vaux DL CrmA expression in T lymphocytes of transgenic mice inhibits CD95 (Fas/APO-1)-transduced apoptosis, but does not cause lymphadenopathy or autoimmune disease. EMBO J 1996; 15:5167-5176.
6. Schmidt S, Rainer J, Ploner C, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 2004; 11 (Suppl 1):S45-55.
7. Helmberg A, Auphan N, Caelles C, Karin M. Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor. EMBO J 1995; 14:452-460.
8. Wisniewska M, Stanczyk M, Grzelakowska-Sztabert B, Kaminska B. Nuclear factor of activated T cells (NFAT) is a possible target for dexamethasone in thymocyte apoptosis. Cell Biol Int 1997; 21:127-132.
9. Ayroldi E, Zollo O, Bastianelli A, et al. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest 2007; 117:1605-1615.
10. Nuutinen U, Ropponen A, Suoranta S, et al. Dexamethasone-induced apoptosis and up-regulation of Bim is dependent on glycogen synthase kinase-3. Leuk Res 2009; 33:1714-1717.
11. Spokoini R, Kfir-Erenfeld S, Yefenof E, Sionov RV. Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis. Mol Endocrinol 2010; 24:1136-1150.
12. Grander D, Kharaziha P, Laane E, et al. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy 2009; 5:1198-1200.
13. Laane E,Tamm KP, Buentke E, et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009; 16:1018-1029.
14. Ploner C, Schmidt S, Presul E, et al. Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia. J Steroid Biochem Mol Biol 2005; 93:153-160.
15. Swerdlow S, McColl K, Rong Y, et al. Apoptosis inhibition by Bcl-2 gives way to autophagy in glucocorticoid-treated lymphocytes. Autophagy 2008; 4:612-620.
16. Geppert M, Ostertag CB, Seitz G, Kiessling M. Glucocorticoid therapy obscures the diagnosis of cerebral lymphoma. Acta Neuropathol (Berl) 1990; 80:629-634.
17. Choi YL, Suh YL, Kim D, et al. Malignant lymphoma of the central nervous system: difficult histologic diagnosis after glucocorticoid therapy prior to biopsy. Clin Neuropathol 2006; 25:29-36.
18. Weller M. Glucocorticoid treatment of primary CNS lymphoma. J Neurooncol 1999; 43:237-239.
19. Wright RL, Shaumba B, Keller J. The effect of glucocorticosteroids on growth and metabolism of experimental glial tumors. J Neurosurg 1969; 30:140-145.
20. Tamargo RJ, Leong KW, Brem H. Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J Neurooncol 1990; 9:131-138.
21. Badruddoja MA, Krouwer HG, Rand SD, et al. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro Oncol 2003; 5:235-243.
22. Villeneuve J, Galarneau H, Beaudet MJ, et al. Reduced glioma growth following dexamethasone or antiangiopoietin 2 treatment. Brain Pathol 2008; 18:401-414.
23. Goh JJ, See SJ, Ang E, Ng WH. Vanishing glioblastoma after corticosteroid therapy. J Clin Neurosci 2009; 16:1226-1228.
24. Langeveld CH, van Waas MP, Stoof JC, et al. Implication of glucocorticoid receptors in the stimulation of human glioma cell proliferation by dexamethasone. J Neurosci Res 1992; 31:524-531.
25. Zibera C, Gibelli N, Butti G, et al. Proliferative effect of dexamethasone on a human glioblastoma cell line (HU 197) is mediated by glucocorticoid receptors. Anticancer Res 1992; 12:1571-1574.
26. Weller M, Schmidt C, Roth W, Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology 1997; 48:1704-1709.
27. Zhang C, Wenger T, Mattern J, et al. Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther 2007; 6:278-287.
28. Das A, Banik NL, Ray SK. Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells. Cancer Invest 2008; 26:352-358.
29. Narang VS, Fraga C, Kumar N, et al. Dexamethasone increases expression and activity of multidrug resistance transporters at the rat blood-brain barrier. Am J Physiol Cell Physiol 2008; 295:C440-C450.
30. Zuccoli G, Marcello N, Pisanello A, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted keto-genic diet: case report. Nutr Metab (Lond) 2010; 7:33.
31. Piette C, Munaut C, Foidart JM, Deprez M. Treating gliomas with glucocorticoids: from bedside to bench. Acta Neuropathol (Berl) 2006; 112:651-664.
32. Vecht CJ, Hovestadt A, Verbiest HB, et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44:675-680.
33. Guerin C, Wolff JE, Laterra J, et al. Vascular differentiation and glucose transporter expression in rat gliomas: effects of steroids. Ann Neurol 1992; 31:481-487.
34. Forster C, Waschke J, Burek M, et al. Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain specific. J Physiol 2006; 573:413-425.
35. Tamargo RJ, Sills AK Jr, Reinhard CS, et al. Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. J Neurosurg 1991; 74:956-961.
36. Ewing JR, Brown SL, Nagaraja TN, et al. MRI measurement of change in vascular parameters in the 9L rat cerebral tumor after dexamethasone administration. J Magn Reson Imaging 2008; 27:1430-1438.
37. Harke N, Leers J, Kietz S, et al. Glucocorticoids regulate the human occludin gene through a single imperfect palindromic glucocorticoid response element. Mol Cell Endocrinol 2008; 295:39-47.
38. Gu YT, Qin LJ, Qin X, Xu F. The molecular mechanism of dexamethasone-mediated effect on the blood-brain tumor barrier permeability in a rat brain tumor model. Neurosci Lett 2009; 452:114-118.
39. Kim H, Lee JM, Park JS, et al. Dexamethasone coordinately regulates angiopoietin-1 and VEGF: a mechanism of glucocorticoid-induced stabilization of blood-brain barrier. Biochem Biophys Res Commun 2008; 372:243-248.
40. Kroll S, El-Gindi J, Thanabalasundaram G, et al. Control of the blood-brain barrier by glucocorticoids and the cells of the neurovascular unit. Ann N Y Acad Sci 2009; 1165:228-239.
41. Jarden JO, Dhawan V, Moeller JR, et al. The time course of steroid action on blood-to-brain and blood-to-tumor transport of 82Rb: a positron emission tomographic study. Ann Neurol 1989; 25:239-245.
42. Ostergaard L, Hochberg FH, Rabinov JD, et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. J Neurosurg 1999; 90:300-305.
43. Sinha S, Bastin ME, Wardlaw JM, et al. Effects of dexamethasone on peritumoural oedematous brain: a DT-MRI study. J Neurol Neurosurg Psychiatry 2004; 75:1632-1635.
44. Bastin ME, Carpenter TK, Armitage PA, et al. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol 2006; 27:402-408.
45. Armitage PA, Schwindack C, Bastin ME, Whittle IR. Pretreatment tumoural perfusion correlates with an imaging-based response to dexamethasone in patients with glioblastoma multiforme. J Neurol Neurosurg Psychiatry 2010; 81:446-448.
46. Wolfson AH, Snodgrass SM, Schwade JG, et al. The role of steroids in the management of metastatic carcinoma to the brain. A pilot prospective trial. Am J Clin Oncol 1994; 17:234-238.
47. Hempen C, Weiss E, Hess CF. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? Support Care Cancer 2002; 10:322-328.
48. Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 2008; 16:1041-1048.
49. Sarin R, Murthy V. Medical decompressive therapy for primary and metastatic intracranial tumours. Lancet Neurol 2003; 2:357-365.
50. Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96:103-114.
51. Lieberman A, LeBrun Y, Glass P, et al. Use of high dose corticosteroids in patients with inoperable brain tumours. J Neurol Neurosurg Psychiatry 1977; 40:678-682.
52. Chalk JB, Ridgeway K, Brophy T, et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neurosurg Psychiatry 1984; 47:1087-1090. (Pubitemid 14006191)
53. Ruegg S. Dexamethasone/phenytoin interactions: neurooncological concerns. Swiss Med Wkly 2002; 132:425-426.
54. Millar BM, Bezjak A, Tsao M, et al. Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases. Clin Oncol (R Coll Radiol) 2004; 16:339-344.
55. Marantidou A, Levy C, Duquesne A, et al. Steroid requirements during radiotherapy for malignant gliomas. J Neurooncol 2010 [Epub ahead of print].
56. Graham PH, Capp A, Delaney G, et al. A pilot randomised comparison of dexamethasone 96 mg vs 16 mg per day for malignant spinal-cord compression treated by radiotherapy: TROG 01.05 Superdex study. Clin Oncol (R Coll Radiol) 2006; 18:70-76.
57. Happold C, Ernemann U, Roth P, et al. Anticoagulation for radiation-induced neurotoxicity revisited. J Neurooncol 2008; 90:357-362.
58. Weissman DE, Janjan NA, Erickson B, et al. Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. J Neurooncol 1991; 11:235-239.
59. Oki K, Yamane K. Therapies for adrenal insufficiency. Expert Opin Pharmac-other 2007; 8:1283-1291.
60. Hahner S, Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab 2009; 23:167-179.
61. Derr RL, Ye X, Islas MU, et al. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 2009; 27:1082-1086.
62. Bowyer SL, LaMothe MP, Hollister JR. Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985; 76:234-242.
63. Dirks-Naylor AJ, Griffiths CL. Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy. J Steroid Biochem Mol Biol 2009; 117:1-7.
64. Owczarek J, Jasinska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 2005; 57:23-34.
65. Oshima Y, Kuroda Y, Kunishige M, et al. Oxidative stress-associated mitochondrial dysfunction in corticosteroid-treated muscle cells. Muscle Nerve 2004; 30:49-54.
66. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skelet al muscle atrophy. Science 2001; 294:1704-1708.
67. Schakman O, Gilson H, de Coninck V, et al. Insulin-like growth factor-I gene transfer by electroporation prevents skelet al muscle atrophy in glucocorticoid-treated rats. Endocrinology 2005; 146:1789-1797.
68. Clarke BA, Drujan D, Willis MS, et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skelet al muscle. Cell Metab 2007; 6:376-385.
69. Wen PY, Schiff D, Kesari S, et al. Medical management of patients with brain tumors. J Neurooncol 2006; 80:313-332.
70. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 2007; 18:1319-1328.
71. Caplan L, Saag KG. Glucocorticoids and the risk of osteoporosis. Expert Opin Drug Saf 2009; 8:33-47.
72. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblas-togenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102:274-282.
73. Rauch A, Seitz S, Baschant U, et al. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab 2010; 11:517-531.
74. Hougardy DM, Peterson GM, Bleasel MD, Randall CT. Is enough attention being given to the adverse effects of corticosteroid therapy? J Clin Pharm Ther 2000; 25:227-234.
75. Amin S, Lavalley MP, Simms RW, Felson DT. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002; 17:1512-1526.
76. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357:2028-2039.
77. Compston J. Management of glucocorticoid-induced osteoporosis. Nat Rev Rheumatol 2010; 6:82-88.
78. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125:961-968.
79. Boonen S, Vanderschueren D, Haentjens P, Lips P. Calcium and vitamin D in the prevention and treatment of osteoporosis: a clinical update. J Intern Med 2006; 259:539-552.
80. Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary osteoporosis. Eur J Endocrinol 2010; 162:1009-1020.
81. Zoorob RJ, Cender D. A different look at corticosteroids. Am Fam Physician 1998; 58:443-450.
82. Henson JW, Jalaj JK, Walker RW, et al. Pneumocystis carinii pneumonia in patients with primary brain tumors. Arch Neurol 1991; 48:406-409.
83. Slivka A, Wen PY, Shea WM, Loeffler JS. Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors. Am J Med 1993; 94:216-219.
84. Enomoto T, Azuma A, Matsumoto A, et al. Preventive effect of sulfamethox-asole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia. Intern Med 2008; 47:15-20.
85. Stamp LK, Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol 2010; 37:686-688.
86. Streffer JR, Bitzer M, Schabet M, et al. Response of radiochemotherapy- associated cerebral edema to a phytotherapeutic agent, H15. Neurology 2001; 56:1219-1221.
87. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27:4733-4740.
88. Kamoun WS, Ley CD, Farrar CT, et al. Edema control by cediranib, avascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009; 27:2542-2552.